Guofan Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guofan Jin has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
Jiankang Feng
School of Pharmacy, Jiangsu University, Zhenjiang, CHINA
17 shared publicationsShuo Wang
16 shared publicationsTiantian Chai
School of Pharmacy Jiangsu University Zhenjiang P. R. China
15 shared publicationsMengtong Zhang
School of Pharmacy Jiangsu University Zhenjiang P. R. China
13 shared publicationsYing Liu
School of Pharmacy, Jiangsu University, Zhenjiang, CHINA
13 shared publicationsFuyan Xiao
School of Pharmacy, Jiangsu University, Zhenjiang 212013, PR China
12 shared publications
Latest Publications
- 20 March 2026
- Published by Springer Nature in Colloid and Polymer Science
- Vol. 304 (6) , 1341-1359
Glycyrrhizic acid-encapsulated emodin and IR-813 nanocomposite with clump-encapsulated and approximately spherical morphology: pH-responsive release, in vitro anti-tumor activity and cell targeting study
- 20 March 2026
- Published by Springer Nature in Colloid and Polymer Science
- Vol. 304 (6) , 1341-1359
Glycyrrhizic acid-encapsulated emodin and IR-813 nanocomposite with clump-encapsulated and approximately spherical morphology: pH-responsive release, in vitro anti-tumor activity and cell targeting study
- 26 December 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (13) , e04018
pH‐Triggered and Targeted Delivery of Curcumin: From Dendritic Polymers to Natural and Synthetic Nanocarriers
Curcumin, a bioactive compound with broad therapeutic potential, faces critical challenges in clinical translation due to its low water solubility, poor bioavailability, and rapid metabolism. This review provides a comprehensive and critical overview of recent advances in curcumin delivery systems, with a particular emphasis on dendritic polymer‐based strategies and pH‐responsive formulations. We first highlight the rational design and fabrication of curcumin–dendrimer conjugates through self‐assembly and covalent coupling, emphasizing their enhanced targeting efficiency, stability, and intrinsic fluorescence for bioimaging applications. Next, we explore how dual‐function systems—integrating pH sensitivity with co‐delivery or imaging functions—can overcome conventional delivery barriers. Special attention is given to nanoformulations using natural polysaccharides and Eudragit coatings that enable controlled, site‐specific release in acidic tumor microenvironments. By evaluating current limitations and proposing future directions, this review aims to inspire the development of more robust, multifunctional, and clinically translatable curcumin‐based nanotherapeutics.
- 26 December 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (13) , e04018
pH‐Triggered and Targeted Delivery of Curcumin: From Dendritic Polymers to Natural and Synthetic Nanocarriers
Curcumin, a bioactive compound with broad therapeutic potential, faces critical challenges in clinical translation due to its low water solubility, poor bioavailability, and rapid metabolism. This review provides a comprehensive and critical overview of recent advances in curcumin delivery systems, with a particular emphasis on dendritic polymer‐based strategies and pH‐responsive formulations. We first highlight the rational design and fabrication of curcumin–dendrimer conjugates through self‐assembly and covalent coupling, emphasizing their enhanced targeting efficiency, stability, and intrinsic fluorescence for bioimaging applications. Next, we explore how dual‐function systems—integrating pH sensitivity with co‐delivery or imaging functions—can overcome conventional delivery barriers. Special attention is given to nanoformulations using natural polysaccharides and Eudragit coatings that enable controlled, site‐specific release in acidic tumor microenvironments. By evaluating current limitations and proposing future directions, this review aims to inspire the development of more robust, multifunctional, and clinically translatable curcumin‐based nanotherapeutics.
- 20 November 2025
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 348 (Pt 1) , 127227
Photophysical behavior of sulfur-oxidized sulfone and trifluoromethyl-BODIPY: Insight into the relationship between crystal structure and tumor cell imaging
- 20 November 2025
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 348 (Pt 1) , 127227
Photophysical behavior of sulfur-oxidized sulfone and trifluoromethyl-BODIPY: Insight into the relationship between crystal structure and tumor cell imaging
- Open Access
- 15 October 2025
- Published by Springer Nature in Journal of Saudi Chemical Society
- Vol. 29 (5) , 1-17
Synthesis, cell imaging, biological evaluation and molecular docking studies of novel benzenesulfonyl-substituted curcumin ligand iridium (III) complexes as anti-tumor drugs
- 15 October 2025
- Published by Springer Nature in Journal of Saudi Chemical Society
- Vol. 29 (5) , 1-17
Open AccessSynthesis, cell imaging, biological evaluation and molecular docking studies of novel benzenesulfonyl-substituted curcumin ligand iridium (III) complexes as anti-tumor drugs
- Open Access
- 29 August 2025
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 18, 1082024-8
A multi-component fluorescence composite strategy for constructing a mesh coating pattern: Design, synthesis, cell imaging, and bioactivity study of a visual antitumor fluorescent complex
A novel visualized anti-tumor complex was designed to accomplish the targeting and visualization of anti-tumor drugs, thereby reducing adverse drug reactions and achieving precision medicine. One-pot fluorescent complexes were created using isorhamnetin, nido-carborane, and rhodamine B as raw materials. By embedding these complexes in four medicinal acrylic resins, which are high molecular-weight polymers prepared by polymerization reactions of acrylic acid or methacrylic acid and their ester monomers, a series of fluorescent anti-tumor complexes Eudragit® L 100-55@isorhamnetin/nido-carborane/rhodamine B (L-ICR), Eudragit® E PO@isorhamnetin/nido-carborane/rhodamine B (E-ICR), Eudragit® RS 100@isorhamnetin/nido-carborane/rhodamine B (S-ICR), and Eudragit® RL 100@isorhamnetin/nido-carborane/rhodamine B (R-ICR) were created, which enhanced the bioavailability and stability of isorhamnetin and nido-carborane and made it possible to see the specific locations where medications were targeted. L-ICR was then screened using the cell proliferation toxicity test (CCK8), which had a greater anti-tumor effect. As the concentration of L-ICR reached 24 µg/mL, the inhibition rate of HeLa cells and PC3 cells was 67.66% and 48.25%, respectively. Using transmission electron microscopy (TEM), it was observed that the internal microstructure of L-ICR was tightly wrapped in an acrylic resin network. According to in vitro tumor cell imaging experiments, L-ICR exhibited good biocompatibility and selectivity, as most tumor cells were successfully entered into the nucleus. The complex in this study was a good fluorescent anti-tumor complex, with great imaging and targeting effect, and anti-tumor ability, which provided a new idea for the further development of anti-tumor drugs in the future.
- 29 August 2025
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 18, 1082024-8
Open AccessA multi-component fluorescence composite strategy for constructing a mesh coating pattern: Design, synthesis, cell imaging, and bioactivity study of a visual antitumor fluorescent complex
A novel visualized anti-tumor complex was designed to accomplish the targeting and visualization of anti-tumor drugs, thereby reducing adverse drug reactions and achieving precision medicine. One-pot fluorescent complexes were created using isorhamnetin, nido-carborane, and rhodamine B as raw materials. By embedding these complexes in four medicinal acrylic resins, which are high molecular-weight polymers prepared by polymerization reactions of acrylic acid or methacrylic acid and their ester monomers, a series of fluorescent anti-tumor complexes Eudragit® L 100-55@isorhamnetin/nido-carborane/rhodamine B (L-ICR), Eudragit® E PO@isorhamnetin/nido-carborane/rhodamine B (E-ICR), Eudragit® RS 100@isorhamnetin/nido-carborane/rhodamine B (S-ICR), and Eudragit® RL 100@isorhamnetin/nido-carborane/rhodamine B (R-ICR) were created, which enhanced the bioavailability and stability of isorhamnetin and nido-carborane and made it possible to see the specific locations where medications were targeted. L-ICR was then screened using the cell proliferation toxicity test (CCK8), which had a greater anti-tumor effect. As the concentration of L-ICR reached 24 µg/mL, the inhibition rate of HeLa cells and PC3 cells was 67.66% and 48.25%, respectively. Using transmission electron microscopy (TEM), it was observed that the internal microstructure of L-ICR was tightly wrapped in an acrylic resin network. According to in vitro tumor cell imaging experiments, L-ICR exhibited good biocompatibility and selectivity, as most tumor cells were successfully entered into the nucleus. The complex in this study was a good fluorescent anti-tumor complex, with great imaging and targeting effect, and anti-tumor ability, which provided a new idea for the further development of anti-tumor drugs in the future.
- Open Access
- 21 May 2025
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 37, 3222024-11
Acrylic resin-coated rhodamine-6G/isorhamnetin/nido-carborane fluorescent complexes: Photophysical properties, drug release, and tumor cell imaging studies
Biocompatibility and solubility problems of the isorhamnetin-nido-carborane complex were resolved by creating four fluorescent complexes using a one-pot method: L100-55@rhodamine-6G/isorhamnetin/nido-carborane (RIC-1), EPO@rhodamine-6G/isorhamnetin/nido-carborane (RIC-2), RS@rhodamine-6G/isorhamnetin/nido-carborane (RIC-3), and RL@rhodamine-6G/isorhamnetin/nido-carborane (RIC-4). When it came to UV absorption stability, RIC-1 was unique among them. Transmission electron microscopy (TEM) analysis shows that RIC-1 forms a flocculent, network-like structure in the acrylic matrix with uniform dispersion, indicating a stable complex. Cytotoxicity and therapeutic potential were evaluated using CCK8 and cell uptake assays. With inhibition rates of 49-56% and 55-62%, respectively, RIC-1 showed low cytotoxicity and strong anti-tumor efficacy, specifically targeting PC3 and HeLa tumor cells. This study emphasizes the potential of this fluorescent complex, in particular RIC-1, for targeted cancer therapy as well as for better tumor imaging and therapeutic applications.
- 21 May 2025
- Published by Scientific Scholar in Journal of King Saud University – Science
- Vol. 37, 3222024-11
Open AccessAcrylic resin-coated rhodamine-6G/isorhamnetin/nido-carborane fluorescent complexes: Photophysical properties, drug release, and tumor cell imaging studies
Biocompatibility and solubility problems of the isorhamnetin-nido-carborane complex were resolved by creating four fluorescent complexes using a one-pot method: L100-55@rhodamine-6G/isorhamnetin/nido-carborane (RIC-1), EPO@rhodamine-6G/isorhamnetin/nido-carborane (RIC-2), RS@rhodamine-6G/isorhamnetin/nido-carborane (RIC-3), and RL@rhodamine-6G/isorhamnetin/nido-carborane (RIC-4). When it came to UV absorption stability, RIC-1 was unique among them. Transmission electron microscopy (TEM) analysis shows that RIC-1 forms a flocculent, network-like structure in the acrylic matrix with uniform dispersion, indicating a stable complex. Cytotoxicity and therapeutic potential were evaluated using CCK8 and cell uptake assays. With inhibition rates of 49-56% and 55-62%, respectively, RIC-1 showed low cytotoxicity and strong anti-tumor efficacy, specifically targeting PC3 and HeLa tumor cells. This study emphasizes the potential of this fluorescent complex, in particular RIC-1, for targeted cancer therapy as well as for better tumor imaging and therapeutic applications.